Fractyl Health, Inc. (GUTS)
NASDAQ: GUTS · Real-Time Price · USD
1.205
-0.055 (-4.37%)
Apr 28, 2025, 4:00 PM EDT - Market closed
Fractyl Health Employees
Fractyl Health had 107 employees as of December 31, 2024. The number of employees increased by 5 or 4.90% compared to the previous year.
Employees
107
Change (1Y)
5
Growth (1Y)
4.90%
Revenue / Employee
$869
Profits / Employee
-$658,234
Market Cap
58.70M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 107 | 5 | 4.90% |
| Dec 31, 2023 | 102 | 19 | 22.89% |
| Dec 31, 2021 | 83 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
GUTS News
- 10 hours ago - Fractyl Health to Present Compelling Preclinical Data from its Rejuva® Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting - GlobeNewsWire
- 27 days ago - Fractyl Health Reports Positive Early Data Showing Revita® Has Potential to Prevent Weight Regain After GLP-1 Discontinuation - GlobeNewsWire
- 2 months ago - Fractyl Health, Inc. (GUTS) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Fractyl Health Announces Fourth Quarter and Full Year 2024 Financial Results and Business Updates - GlobeNewsWire
- 2 months ago - Fractyl Health to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Updates on March 3, 2025 - GlobeNewsWire
- 3 months ago - Fractyl Health Announces Increased Focus on Groundbreaking Revita® Weight Maintenance and Rejuva® Pancreatic Gene Therapy Programs with Potential to Deliver Key Clinical Milestones Across Multiple Studies in 2025 - GlobeNewsWire
- 4 months ago - Fractyl Health Unveils Promising Preclinical Data Demonstrating Safety and Feasibility of Local Delivery of RJVA-001 Rejuva® Smart GLP-1™ Pancreatic Gene Therapy at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC) - GlobeNewsWire
- 5 months ago - Fractyl Health to Present New Preclinical Data from its Rejuva® Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC) - GlobeNewsWire